TORONTO, Jan. 25, 2012 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign") and EasyMed Services, Inc. (CNSX: EZM) (OTCBB: EMYSF) ("EasyMed") are pleased to announce they have executed agreements that allow the resale and distribution of each other's respective products as well as a Development and License Agreement for the creation of a joint product offering.
Under the terms of the Agreements:
- Biosign will have access to resell and distribute EasyMed products within North America;
- EasyMed will have access to resell and distribute Biosign products within Europe;
- Biosign and EasyMed shall jointly develop new healthcare products and will share the revenue and intellectual property equally;
- EasyMed shall become a mobile technology provider for Biosign's future release of Healthanywhere™; and
- Biosign shall promote the "Powered by EasyMed" brand.
As previously reported (see news December 5th, 2011), the companies intend to interface UFIT® devices into Easy SmartCare and will make the offering available within their respective territories. The combined solution provides benefits for payers, providers, and patients through improved patient preparation for medical visits, decreased absenteeism, better information for both the patient and the caregiver, improved communication of medical results to the patient, and enhanced outpatient management.
"We were looking for ways to increase patient access to our system and we have found a great mobility partner in EasyMed" stated Dr. Scott Jenkins, CEO of Biosign, adding "Together our companies are striving to provide the solutions that enable people to better manage their health"
Andrew Ritchie, CEO of EasyMed commented, "The partnership between Biosign and EasyMed will allow both companies to strengthen our product offering and take advantage of our strong sales contacts in each of our markets. We also believe that by developing a new product range that takes advantage of both companies existing products and technology, that we will meet a new growing demand by customers to be connected to their healthcare professionals by mobile or internet technology. We are very pleased we were able to conclude the agreements and can now start the process of building a new solution for healthcare"
About EasyMed Services, Inc.
EasyMed Services, Inc. (CNSX: EZM) (OTCBB: EMYSF) provides technology solutions for healthcare organizations to enable the delivery of healthcare services on mobile devices while saving costs and improving operational efficiency. The technology platform implements the latest industry standards, is readily integrated into existing hospital environments, and complies with HIPAA and multi-national regulations. For more information on EasyMed, please visit: www.EasyMedmobile.com.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, lifestyle, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information: